New directions in the neoadjuvant treatment of HER2+ breast cancer

摘要: Approximately 20% of breast cancer demonstrates amplification the HER2 gene resulting in overexpression protein on cell surface. Effective targeting with anti-HER2 monoclonal antibodies (trastuzumab, pertuzumab, trastuzumab-emtansine) and tyrosine kinase inhibitors (lapatinib) dramatically improves natural history this aggressive disease. Patients HER2-overexpressing (HER2+) achieve higher rates pathologic complete response (pCR) to cytotoxic chemotherapy HER2-targeted therapy neoadjuvant trials compared less subtypes. Moreover, a trend toward positive correlation between pCR improved long-term survival appears be emerging clinical trials. This article reviews various definitions as an end point summarizes use anti-HER2-targeted agents setting for HER2+